Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)

Introduction: Membranoproliferative glomerulonephritis type II or dense deposit disease (MPGN II/DDD) causes chronic renal dysfunction that progresses to end stage renal disease in about half of patients within 10 years of diagnosis. Deficiency of and mutations in the complement factor H (CFH) gene are associated with the development of MPGN II/DDD, suggesting that dysregulation of the alternative pathway of the complement cascade is important in disease pathophysiology. Subjects: Patients with MPGN II/DDD were studied to determine whether specific allele variants of CFH and CFHR5 segregate preferentially with the MPGN II/DDD disease phenotype. The control group was compromised of 131 people in whom age related macular degeneration had been excluded. Results: Allele frequencies of four single nucleotide polymorphisms in CFH and three in CFHR5 were significantly different between MPGN II/DDD patients and controls. Conclusion: We have identified specific allele variants of CFH and CFHR5 associated with the MPGN II/DDD disease phenotype. While our data can be interpreted to further implicate complement in the pathogenesis of MPGN II/DDD, these associations could also be unrelated to disease pathophysiology. Functional studies are required to resolve this question.

[1]  R. Gokal,et al.  Fundus changes in mesangiocapillary glomerulonephritis type II: clinical and fluorescein angiographic findings. , 1989, The British journal of ophthalmology.

[2]  P. Hill,et al.  Factor H-related protein-5: a novel component of human glomerular immune deposits. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  Wiklund Ra,et al.  First of two parts , 1997 .

[4]  M. Daha,et al.  Differential expression of complement components in human fetal and adult kidneys. , 1996, Kidney international.

[5]  C. Bazzi,et al.  The prognostic value of some clinical and histological parameters in membranoproliferative glomerulonephritis (MPGN): report of 112 cases. , 1977, Nephron.

[6]  D. Colville,et al.  Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II ("dense deposit disease"). , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  M. Walport Complement. First of two parts. , 2001, The New England journal of medicine.

[8]  Robert F. Mullins,et al.  An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration , 2001, Progress in Retinal and Eye Research.

[9]  M. Gubler,et al.  Dense deposit disease: a variant of membranoproliferative glomerulonephritis. , 1975, Kidney international.

[10]  S. Meri,et al.  Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. , 1994, Biochemical and biophysical research communications.

[11]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[12]  V. Verhasselt,et al.  Regulation of C3 and factor H synthesis of human glomerular mesangial cells by IL‐1 and interferon‐gamma , 1994, Clinical and experimental immunology.

[13]  Albert Hofman,et al.  Epidemiology of age-related maculopathy: a review. , 2003, European journal of epidemiology.

[14]  O. Spiller,et al.  Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. , 2002, Kidney international.

[15]  P. Mcenery Membranoproliferative glomerulonephritis: the Cincinnati experience--cumulative renal survival from 1957 to 1989. , 1990, The Journal of pediatrics.

[16]  G. Hageman,et al.  Structure and composition of drusen associated with glomerulonephritis: Implications for the role of complement activation in drusen biogenesis , 2001, Eye.

[17]  B S Hawkins,et al.  Epidemiology of age-related macular degeneration. , 1999, Molecular vision.

[18]  G. Deschênes,et al.  Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. , 2004, Journal of the American Society of Nephrology : JASN.

[19]  A. Bird,et al.  [Pathogenesis of lesions in late age-related macular disease]. , 2004, Journal francais d'ophtalmologie.

[20]  C. Swainson,et al.  Mesangiocapillary glomerulonephritis: A long‐term study of 40 cases , 1983, The Journal of pathology.

[21]  Robert F Mullins,et al.  A role for local inflammation in the formation of drusen in the aging eye. , 2002, American journal of ophthalmology.

[22]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[23]  A. Hofman,et al.  REVIEW: Epidemiology of age-related maculopathy: a review , 2003, European Journal of Epidemiology.

[24]  John D Lambris,et al.  Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  R. Sandler,et al.  Infantile cystinosis presenting as chronic constipation. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  C. Antignac,et al.  Glomerular lesions in the transplanted kidney in children. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  M. Walport,et al.  Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H , 2002, Nature Genetics.

[28]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[29]  R. Trembath,et al.  Pendred syndrome and DFNB4‐mutation screening of SLC26A4 by denaturing high‐performance liquid chromatography and the identification of eleven novel mutations , 2004, American journal of medical genetics. Part A.

[30]  G. Haycock,et al.  Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. , 1983, The American journal of medicine.

[31]  Stefan Heinen,et al.  Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. , 2003, The Journal of clinical investigation.

[32]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[33]  P. Zipfel,et al.  The role of complement in membranoproliferative glomerulonephritis , 2006 .

[34]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Nangaku Complement regulatory proteins in glomerular diseases. , 1998, Kidney international.

[36]  N. Gretz,et al.  Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long‐term follow‐up , 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[37]  J. H. Jansen,et al.  In situ complement activation in porcine membranoproliferative glomerulonephritis type II. , 1998, Kidney international.

[38]  P Vivien,et al.  [The nephrotic syndrome]. , 1965, Le Progres medical.